Join nephrologist Dr. Vivek Bhalla (@BhallaResearch)
& Science Communicator Rebecca Handler (@rmh199) in the lab as he shares a story that began with a single patient’s case of early-onset kidney disease and led to a genetic discovery: youtube.com/watch?v=q0hiPi3_…#Nephrology
⟳ Laboratory of Vivek Bhalla, MD- Stanford retweeted
The bestselling author of Cutting for Stone and The Covenant of Water is coming to WCN’27!
In a world of rapidly advancing technology, could the most powerful tool in medicine still be human connection?
Be there for a thought-provoking plenary session with renowned physician, storyteller and New York Times bestselling author Professor @abe_verghese, as he explores the importance of human connection in medicine and why listening, empathy, and the relationship between patients and clinicians remain essential.
🔎 Discover more about Professor Verghese and his plenary session:
bit.ly/4zj4VzL
🌏 Be part of WCN’27 in Kuala Lumpur, April 1–4, 2027!
🎟️ Register at the early bird rate by January 13, 2027:
bit.ly/3VvEvg2.
Combine 2027 ISN membership with WCN'27 registration and save: bit.ly/4zvkPaz#ISNWCN#WCN27#WorldCongress#Congress#Nephrology#KidneyCare#KidneyHealth#MedicalResearch#GlobalHealth#ThisIsISN
⟳ Laboratory of Vivek Bhalla, MD- Stanford retweeted
Among patients with hypertension due to primary aldosteronism, reductions in blood pressure and the aldosterone-to-renin ratio persisted for 2 years after completion of an extended course of aldosterone synthase inhibition. Full study results: nej.md/4jXjULO#ScientificSessions26 | @AHAScience
⟳ Laboratory of Vivek Bhalla, MD- Stanford retweeted
It seems the FDA has finally decided to cross the Rubicon and published a new and revolutionary regulatory framework which aims to expedite the regulatory approval process of new Gene Editing-based treatments - such as $BEAM Base Editing and $PRME Prime Editing.
These new proposed guidelines are the pinnacle of a regulatory process which began with a Cell and Gene Therapy Roundtable - held last year by FDA former commissioner @MartyMakary and the former director of the FDA’s Center for Biologics Evaluation and Research (CBER) @VPrasadMDMPH, in which researchers, industry leaders and scientists set together with FDA officials to bring new ideas to the table.
During this fascinating meeting Prof. @davidrliu from @Harvard & the @broadinstitute and most importantly the inventor of Base Editing and Prime Editing has made a closing statement which really caught my attention:
“It’s not only about treating 1,000 rare disease patients but about building a modular system that turns rare disease treatment into a national engine for therapeutic innovation and which will secure America’s leadership in Genetic medicine for the foreseeable future.”
It seems that finally Prof Liu’s call was answered!
🚨The FDA’s new draft guidance on individualized genome editing products makes base and prime editing much more practical. Good news for many patients that are still waiting.
▶️ Beam had planned full dose exploration with BEAM-304A for the common R408W mutation in PKU, then adding 304B and 304C to the same master-protocol trial starting at the optimal dose from 304A. Under the guidance, it is now possible that Beam could get approval covering 304B and 304C (and later mutations) with little or no clinical data on those variants, as long as the data from 304A are judged sufficient to support the Individualized Feature Space and the variants meet in vitro criteria.
▶️ Prime Medicine is already dosing patients in its Phase 1/2 trial for PM577a targeting H1069Q in Wilson disease, the most common mutation in US and EU (roughly 30-50%). The same framework could let clinical data on H1069Q support an IFS that covers additional ATP7B mutations, so Prime may not need separate trials for R778L and other variants in US.
I expect Beam and Prime can reach 60%+ patients in PKU and WD quickly with a few guide RNAs/pegRNAs once 304A and H1069Q are approved.
🔥 Both companies are well positioned because they hold the foundational IP in base editing and prime editing and already have modular LNP platforms that fit the IFS model.
$BEAM$PRME
⟳ Laboratory of Vivek Bhalla, MD- Stanford retweeted
Very much looking forward to @AHAScience#ScientificSessions26 starting next week🙌
What a🌟program - Nobel laureate on clinical trials, OpenAI in the room, the first CKM guideline in practice, and so much more👏👏
Gratitude & excitement to co-Chair the🔥Results of the @American_Heart#Health#Equity#Research Network in the Community!
Congratulations @spjuraschek@ycommodore & all presenters & look forward to our session!
⟳ Laboratory of Vivek Bhalla, MD- Stanford retweeted
It was a great experience for our team to present & to hear about great research in the field. With appreciation for novel mechanisms, new diagnostics and new therapies, hypertension is having a moment, and we must all rise to meet it. The future is hopeful for #hypertension care
⟳ Laboratory of Vivek Bhalla, MD- Stanford retweeted
1. CRISPR came from basic research on bacteria.
2. Optogenetics started with a discovery in algae.
3. The GFP protein comes from jellyfish.
The biggest breakthroughs all trace to scientists follow their curiosity. This is one huge reason why we must keep funding basic research!
Listening to past @ASNKidney president @proychaudhuryMD talking about the totality of new therapies of CKD and how to implement them…great time to be in Nephrology
⟳ Laboratory of Vivek Bhalla, MD- Stanford retweeted
D-24 until #Hypertension26 Oct 7-11 in Arlington, VA! We expect phenomenal sessions including cuffless 24hr ABPM in HTN management, SGLT2 inhibition in salt-sensitive HTN🫘↔️🫀, renal denervation for resistant HTN, GLP-1a in lowering BP, and many more! professional.heart.org/en/me…